Expanding Global Biosimilar Market Save

Between 2010 and 2013, $95 billion in branded pharmaceutical patents will have expired, leading to significantly higher sales opportunities for those manufacturing generics and biosimilars. According to IMS Health, Americans will spend $220 billion on biologic medicine by 2017, and that amount is likely to climb with more than 900 biosimilars in development. Roughly $70 billion in branded biologics will lose patent protection by 2018, and that has industry participants forecasting that the market for biosimilars could reach $20 billion as soon as 2020.